PD-1 Regulates the Growth of Human Mastocytosis Cells

被引:24
作者
Kataoka, Tatsuki R. [1 ]
Fujimoto, Masakazu [1 ]
Moriyoshi, Koki [1 ]
Koyanagi, Itsuko [1 ]
Ueshima, Chiyuki [1 ]
Kono, Fumihiko [2 ]
Tsuruyama, Tatsuaki [1 ]
Okayama, Yoshimichi [3 ]
Ra, Chisei [3 ]
Haga, Hironori [1 ]
机构
[1] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto 6068507, Japan
[2] Kyoto City Hosp, Dept Diagnost Pathol, Kyoto, Japan
[3] Nihon Univ, Grad Sch Med Sci, Adv Med Res Ctr, Div Mol Cell Immunol & Allergol, Tokyo, Japan
关键词
inhibitory receptor; KIT; mast cell; mastocytosis; PD-1; PROTOONCOGENE C-KIT; MAST-CELLS; PROGRAMMED DEATH-1; PERIPHERAL-BLOOD; RECEPTOR; ACTIVATION; IDENTIFICATION; ANTI-PD-1; PATIENT; SHP-1;
D O I
10.2332/allergolint.12-OA-0450
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Programmed death-1 (PD-1) is a marker for human neoplastic T cells. Here, we evaluated whether or not PD-1 was also a marker for human mastocytosis, and explored the role of PD-1 in human mastocytosis cells. Methods: Immunohistochemical analysis was used to evaluate the expression of PD-1 in clinical samples of human cutaneous mastocytosis. The expression of PD-1 in human mastocytosis cell lines was checked by RT-PCR, western blotting and flow cytometry. We stimulated human mastocytosis cell lines (LAD2 and HMC1.2) with recombinant ligand for PD-1, PD-L1 (rPD-L1), and tested the proliferative activity and the status of signal molecules by Cell Counting Kit-8 and ELISA, respectively. Results: Ten of 30 human cutaneous mastocytosis cases (33.3%) expressed PD-1 protein. We also found that a human mastocytosis line LAD2 cells expressed PD-1 protein on their surfaces. The administration with rPD-L1 suppressed the stem cell factor-dependent growth of the LAD2 cells. And, rPD-L1 activated SHP-1 and SHP-2 simultaneously, and decreased the phosphorylation of AKT, in LAD2 cells. In contrast, we could not detect the expression of PD-1, and the significant effect of rPD-L1 on the mutated KIT-driven growth of HMC1.2 cells. Conclusions: PD-1 could be a marker for human cutaneous mastocytosis and regulate the growth of human PD-1-positive mastocytosis cells.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 26 条
[21]   Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor [J].
Nishimura, H ;
Nose, M ;
Hiai, H ;
Minato, N ;
Honjo, T .
IMMUNITY, 1999, 11 (02) :141-151
[22]   Development migration, and survival of mast cells [J].
Okayama, Yoshimichi ;
Kawakami, Toshiaki .
IMMUNOLOGIC RESEARCH, 2006, 34 (02) :97-115
[23]   PD-1 and PD-1 ligands: from discovery to clinical application [J].
Okazaki, Taku ;
Honjo, Tasuku .
INTERNATIONAL IMMUNOLOGY, 2007, 19 (07) :813-824
[24]   A SHPing tale: Perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail [J].
Poole, AW ;
Jones, ML .
CELLULAR SIGNALLING, 2005, 17 (11) :1323-1332
[25]   Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy [J].
Stagg, John ;
Loi, Sherene ;
Divisekera, Upulie ;
Ngiow, Shin Foong ;
Duret, Helene ;
Yagita, Hideo ;
Teng, Michele W. ;
Smyth, Mark J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (17) :7142-7147
[26]   Programmed death 1 mRNA in peripheral blood as biomarker of acute renal allograft rejection [J].
Wang Ya-wen ;
Wang Zhen ;
Shi Bing-yi .
CHINESE MEDICAL JOURNAL, 2011, 124 (05) :674-678